These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25111659)

  • 1. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.
    Maier C; Herkommer K; Luedeke M; Rinckleb A; Schrader M; Vogel W
    Prostate; 2014 Oct; 74(14):1444-51. PubMed ID: 25111659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
    Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O'Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; Brady AF; van Os T; Gallagher D; Johannsson O; Donaldson A; Barwell J; Nicolai N; Friedman E; Obeid E; Greenhalgh L; Murthy V; Copakova L; Saya S; McGrath J; Cooke P; Rønlund K; Richardson K; Henderson A; Teo SH; Arun B; Kast K; Dias A; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Eccles DM; Tricker K; Eyfjord J; Falconer A; Foster C; Gronberg H; Hamdy FC; Stefansdottir V; Khoo V; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra A; Moynihan C; Rennert G; Suri M; Wilson P; Dudderidge T; ; Offman J; Kote-Jarai Z; Vickers A; Lilja H; Eeles RA
    Eur Urol; 2019 Dec; 76(6):831-842. PubMed ID: 31537406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
    Bancroft EK; Page EC; Castro E; Lilja H; Vickers A; Sjoberg D; Assel M; Foster CS; Mitchell G; Drew K; Mæhle L; Axcrona K; Evans DG; Bulman B; Eccles D; McBride D; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Selkirk C; Hulick PJ; Bojesen A; Skytte AB; Lam J; Taylor L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Blanco I; Salinas M; Cook J; Rosario DJ; Buys S; Conner T; Ausems MG; Ong KR; Hoffman J; Domchek S; Powers J; Teixeira MR; Maia S; Foulkes WD; Taherian N; Ruijs M; Helderman-van den Enden AT; Izatt L; Davidson R; Adank MA; Walker L; Schmutzler R; Tucker K; Kirk J; Hodgson S; Harris M; Douglas F; Lindeman GJ; Zgajnar J; Tischkowitz M; Clowes VE; Susman R; Ramón y Cajal T; Patcher N; Gadea N; Spigelman A; van Os T; Liljegren A; Side L; Brewer C; Brady AF; Donaldson A; Stefansdottir V; Friedman E; Chen-Shtoyerman R; Amor DJ; Copakova L; Barwell J; Giri VN; Murthy V; Nicolai N; Teo SH; Greenhalgh L; Strom S; Henderson A; McGrath J; Gallagher D; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Costello P; Eyfjord J; Rothwell J; Falconer A; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Kote-Jarai Z; Lubinski J; Axcrona U; Melia J; McKinley J; Mitra AV; Moynihan C; Rennert G; Suri M; Wilson P; Killick E; ; Moss S; Eeles RA
    Eur Urol; 2014 Sep; 66(3):489-99. PubMed ID: 24484606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
    Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
    Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.
    Kote-Jarai Z; Leongamornlert D; Saunders E; Tymrakiewicz M; Castro E; Mahmud N; Guy M; Edwards S; O'Brien L; Sawyer E; Hall A; Wilkinson R; Dadaev T; Goh C; Easton D; ; Goldgar D; Eeles R
    Br J Cancer; 2011 Oct; 105(8):1230-4. PubMed ID: 21952622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rare germline genetic variants and risk of aggressive prostate cancer.
    Nguyen-Dumont T; MacInnis RJ; Steen JA; Theys D; Tsimiklis H; Hammet F; Mahmoodi M; Pope BJ; Park DJ; Mahmood K; Severi G; Bolton D; Milne RL; Giles GG; Southey MC
    Int J Cancer; 2020 Oct; 147(8):2142-2149. PubMed ID: 32338768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
    Edwards SM; Evans DG; Hope Q; Norman AR; Barbachano Y; Bullock S; Kote-Jarai Z; Meitz J; Falconer A; Osin P; Fisher C; Guy M; Jhavar SG; Hall AL; O'Brien LT; Gehr-Swain BN; Wilkinson RA; Forrest MS; Dearnaley DP; Ardern-Jones AT; Page EC; Easton DF; Eeles RA;
    Br J Cancer; 2010 Sep; 103(6):918-24. PubMed ID: 20736950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    Leon P; Cancel-Tassin G; Bourdon V; Buecher B; Oudard S; Brureau L; Jouffe L; Blanchet P; Stoppa-Lyonnet D; Coulet F; Sobol H; Cussenot O
    Prostate; 2021 May; 81(6):318-325. PubMed ID: 33599307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
    Mikropoulos C; Selkirk CGH; Saya S; Bancroft E; Vertosick E; Dadaev T; Brendler C; Page E; Dias A; Evans DG; Rothwell J; Maehle L; Axcrona K; Richardson K; Eccles D; Jensen T; Osther PJ; van Asperen CJ; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Hart R; Glover W; Lam J; Taylor L; Salinas M; Feliubadaló L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Cook J; Rosario DJ; Buys SS; Conner T; Domchek S; Powers J; Ausems MG; Teixeira MR; Maia S; Izatt L; Schmutzler R; Rhiem K; Foulkes WD; Boshari T; Davidson R; Ruijs M; Helderman-van den Enden AT; Andrews L; Walker L; Snape K; Henderson A; Jobson I; Lindeman GJ; Liljegren A; Harris M; Adank MA; Kirk J; Taylor A; Susman R; Chen-Shtoyerman R; Pachter N; Spigelman A; Side L; Zgajnar J; Mora J; Brewer C; Gadea N; Brady AF; Gallagher D; van Os T; Donaldson A; Stefansdottir V; Barwell J; James PA; Murphy D; Friedman E; Nicolai N; Greenhalgh L; Obeid E; Murthy V; Copakova L; McGrath J; Teo SH; Strom S; Kast K; Leongamornlert DA; Chamberlain A; Pope J; Newlin AC; Aaronson N; Ardern-Jones A; Bangma C; Castro E; Dearnaley D; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lubinski J; Grindedal EM; McKinley J; Shackleton K; Mitra AV; Moynihan C; Rennert G; Suri M; Tricker K; ; Moss S; Kote-Jarai Z; Vickers A; Lilja H; Helfand BT; Eeles RA
    Br J Cancer; 2018 Jan; 118(2):266-276. PubMed ID: 29301143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival.
    Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
    Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
    BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
    Mitra A; Fisher C; Foster CS; Jameson C; Barbachanno Y; Bartlett J; Bancroft E; Doherty R; Kote-Jarai Z; Peock S; Easton D; ; Eeles R
    Br J Cancer; 2008 Jan; 98(2):502-7. PubMed ID: 18182994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
    Lee DJ; Hausler R; Le AN; Kelly G; Powers J; Ding J; Feld E; Desai H; Morrison C; Doucette A; Gabriel P; Genetics Center R; Judy RL; Weaver J; Kember R; Damrauer SM; Rader DJ; Domchek SM; Narayan V; Schwartz LE; Maxwell KN
    Eur Urol; 2022 Jun; 81(6):559-567. PubMed ID: 34711450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
    Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C;
    Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
    Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA;
    Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
    Mitra AV; Bancroft EK; Barbachano Y; Page EC; Foster CS; Jameson C; Mitchell G; Lindeman GJ; Stapleton A; Suthers G; Evans DG; Cruger D; Blanco I; Mercer C; Kirk J; Maehle L; Hodgson S; Walker L; Izatt L; Douglas F; Tucker K; Dorkins H; Clowes V; Male A; Donaldson A; Brewer C; Doherty R; Bulman B; Osther PJ; Salinas M; Eccles D; Axcrona K; Jobson I; Newcombe B; Cybulski C; Rubinstein WS; Buys S; Townshend S; Friedman E; Domchek S; Ramon Y Cajal T; Spigelman A; Teo SH; Nicolai N; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Eyfjord J; Falconer A; Grönberg H; Hamdy F; Johannsson O; Khoo V; Kote-Jarai Z; Lilja H; Lubinski J; Melia J; Moynihan C; Peock S; Rennert G; Schröder F; Sibley P; Suri M; Wilson P; Bignon YJ; Strom S; Tischkowitz M; Liljegren A; Ilencikova D; Abele A; Kyriacou K; van Asperen C; Kiemeney L; ; Easton DF; Eeles RA
    BJU Int; 2011 Jan; 107(1):28-39. PubMed ID: 20840664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.
    Gleicher S; Kauffman EC; Kotula L; Bratslavsky G; Vourganti S
    Prostate; 2016 Sep; 76(13):1135-45. PubMed ID: 27225637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
    Mitra AV; Jameson C; Barbachano Y; Sodha N; Kote-Jarai Z; Javed A; Bancroft E; Fletcher A; Cooper C; Peock S; ; Easton D; Eeles R; Foster CS
    Oncol Rep; 2010 Feb; 23(2):299-305. PubMed ID: 20043088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.